Shots:

• Organon to acquire Forendo for a total consideration of $954M including $75M up front, $9M in Forendo debt, $270M upon the achievement of development & regulatory milestones & is eligible to receive $600M in commercial milestones payments. The transaction is expected to close in Dec’21
• The acquisition adds a pipeline of products targeting novel treatments for women’s health. Forendo’s pipeline also includes a preclinical program targeting PCOS
• Forendo’s FOR-6219 is currently being evaluated in P-II clinical development for endometriosis. Preclinical research showed that FOR-6219 inhibited the conversion of low potency estrone into highly potent estradiol in endometriotic lesions ex vivo

  Ref: Organon | Image: Forendo